Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Bone Metastasis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Bone Metastasis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Bone Metastasis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Bone Metastasis-Pipeline Review, H1 2017



Executive Summary

Bone Metastasis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis-Pipeline Review, H1 2017, provides an overview of the Bone Metastasis (Oncology) pipeline landscape.

Bone metastasis occurs when cancer cells spread from their original site to a bone. Signs and symptoms of bone metastasis include bone pain, broken bones, urinary incontinence, bowel incontinence and weakness in the legs. The predisposing factors include certain kinds of cancer (breast, prostate, lung, thyroid, and kidney cancers). Treatment options for bone metastasis are chemotherapy, surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Metastasis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Metastasis (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Metastasis (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 3, 17 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 1 molecules, respectively.

Bone Metastasis (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Metastasis (Oncology).

The pipeline guide reviews pipeline therapeutics for Bone Metastasis (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bone Metastasis (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bone Metastasis (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bone Metastasis (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bone Metastasis (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bone Metastasis (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bone Metastasis-Overview

Bone Metastasis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bone Metastasis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bone Metastasis-Companies Involved in Therapeutics Development

Ablynx NV

Amgen Inc

Amura Holdings Ltd

BiologicsMD Inc

ChemoCentryx Inc

Deciphera Pharmaceuticals LLC

Eli Lilly and Company

Leadiant Biosciences Inc

Lupin Ltd

Mirati Therapeutics Inc

Oncobiologics Inc

Oncodrone BV

OPKO Health Inc

Osteologix Holdings Plc

R Pharm

Redx Pharma Plc

Taiho Pharmaceutical Co Ltd

Terpenoid Therapeutics Inc

Bone Metastasis-Drug Profiles

ADM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALX-0141-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-161-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1644-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1740-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMD-3151-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

calcifediol ER-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-354-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-3014-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

denosumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emibetuzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LG-1980-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NBS-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OCD-155-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

roneparstat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-203-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSF-103-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sitravatinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAS-115-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPH-9-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vicrostatin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bone Metastasis-Dormant Projects

Bone Metastasis-Discontinued Products

Bone Metastasis-Product Development Milestones

Featured News & Press Releases

Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease

May 24, 2011: Daiichi Sankyo and AstraZeneca Announce a Co-Promotion Agreement in Japan for Denosumab, a Treatment of Bone Disorders stemming from Bone Metastasis

May 18, 2011: Amgen To Present XGEVA Data At ASCO Annual Meeting

Dec 10, 2010: Amgen Presents New XGEVA Breast Cancer Skeletal-Related Event Prevention Data At SABCS

Nov 18, 2010: Amgen Receives FDA Approval For XGEVA For Prevention Of Skeletal-Related Events In Patients With Bone Metastases From Solid Tumors

Nov 08, 2010: Amgen Announces Phase III Study Results Of Denosumab In Breast Cancer Patients With Bone Metastases

Nov 08, 2010: Published Results Show Denosumab Superior to Zometa in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer

Oct 11, 2010: Amgen Reports Integrated Analysis Demonstrates That Denosumab Delays Onset Of Bone Complications Compared To Zometa

Jul 17, 2010: Amgen Receives FDA's Priority Review Designation For Denosumab BLA For Reduction Of Skeletal Related Events In Advanced Cancer Patients

May 14, 2010: Amgen Submits Denosumab BLA To FDA For Reduction Of Skeletal Related Events In Cancer Patients

Aug 03, 2009: Amgen Announces Positive Top-Line Results For Denosumab In Bone Metastases Patients Compared To Zometa

Jun 04, 2006: Amgen Announces Phase 2 Interim Data Of Denosumab In Advanced Cancer Patients With Bone Metastases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Bone Metastasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Bone Metastasis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Bone Metastasis-Pipeline by Ablynx NV, H1 2017

Bone Metastasis-Pipeline by Amgen Inc, H1 2017

Bone Metastasis-Pipeline by Amura Holdings Ltd, H1 2017

Bone Metastasis-Pipeline by BiologicsMD Inc, H1 2017

Bone Metastasis-Pipeline by ChemoCentryx Inc, H1 2017

Bone Metastasis-Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Bone Metastasis-Pipeline by Eli Lilly and Company, H1 2017

Bone Metastasis-Pipeline by Leadiant Biosciences Inc, H1 2017

Bone Metastasis-Pipeline by Lupin Ltd, H1 2017

Bone Metastasis-Pipeline by Mirati Therapeutics Inc, H1 2017

Bone Metastasis-Pipeline by Oncobiologics Inc, H1 2017

Bone Metastasis-Pipeline by Oncodrone BV, H1 2017

Bone Metastasis-Pipeline by OPKO Health Inc, H1 2017

Bone Metastasis-Pipeline by Osteologix Holdings Plc, H1 2017

Bone Metastasis-Pipeline by R Pharm, H1 2017

Bone Metastasis-Pipeline by Redx Pharma Plc, H1 2017

Bone Metastasis-Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017

Bone Metastasis-Pipeline by Terpenoid Therapeutics Inc, H1 2017

Bone Metastasis-Dormant Projects, H1 2017

Bone Metastasis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Bone Metastasis-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Ablynx NV, Amgen Inc, Amura Holdings Ltd, BiologicsMD Inc, ChemoCentryx Inc, Deciphera Pharmaceuticals LLC, Eli Lilly and Company, Leadiant Biosciences Inc, Lupin Ltd, Mirati Therapeutics Inc, Oncobiologics Inc, Oncodrone BV, OPKO Health Inc, Osteologix Holdings Plc, R Pharm, Redx Pharma Plc, Taiho Pharmaceutical Co Ltd, Terpenoid Therapeutics Inc

Bone Metastasis Therapeutic Products under Development, Key Players in Bone Metastasis Therapeutics, Bone Metastasis Pipeline Overview, Bone Metastasis Pipeline, Bone Metastasis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand